This pivotal article by Ling et al. in the August 2002 issue of Molecular Cancer Therapeutics
addressed the mechanism by which a novel proteasome inhibitor, PS341 (bortezomib) …

Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

Inhibition of the 20S proteasome by bortezomib (Velcade) constitutes a successfully applied
therapy for blood cancer. However, emerging resistance restricts its medicinal use. For …

Proteasomes are large, multicatalytic protein complexes that cleave cellular proteins into
peptides. There are many distinct forms of proteasomes that differ in catalytically active …

Proteasome inhibitors are emerging as effective drugs for the treatment of multiple myeloma
and possibly certain subtypes of non-Hodgkin's lymphoma. Bortezomib (Velcade) is the first …

Proteasome inhibitors represent novel anti-cancer drugs which interact with the proteasome–
ubiquitin pathway. The 26S proteasome is a multicatalytic threonine protease with three …

Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome that is indicated
for single-agent use in the treatment of patients with multiple myeloma who have received at …

Therapeutic strategies for multiple myeloma have dramatically changed in the last two
decades, especially after the introduction of proteasome inhibitors. The first-in-class …

The proteasome is a multicatalytic proteinase complex responsible for the degradation of
most intracellular proteins, including proteins crucial to cell cycle regulation and …

Proteasomes have a fundamental function since they degrade numerous different proteins,
including those involved in the regulation of the cell cycle. Proteasome inhibition is a novel …